Cognoptix Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes
7/15/2013 9:47:34 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ACTON, Mass.--(BUSINESS WIRE)--Cognoptix, an emerging medical device company, will present clinical data in a poster session on Wednesday, July 17, 11:45 a.m.—2:15 p.m. EDT, at the Alzheimer’s Association International Conference (AAIC) that its SAPPHIRE II eye test identified Alzheimer’s disease patients via a beta amyloid (“Ab”) signature in their eyes in a 10-subject proof-of-concept clinical trial. By detecting a specific fluorescent signature of ligand-marked beta amyloid in the supranucleus region of the human lens, SAPPHIRE II achieved a 200% differentiation factor between a group of five healthy volunteers and a group of five patients diagnosed with probable Alzheimer’s disease.
Help employers find you! Check out all the jobs and post your resume.
comments powered by